GLP-1 and health: Beyond weight loss in the Ozempic era (SACRAMENTO) This week, the White House announced a deal with Eli Lilly and Novo Nordisk to lower the cost of their GLP-1 weight loss drugs, Wegovy and Zepbound
Key drivers fueling this momentum include a strong product pipeline with innovative molecules and combination therapies, and increased healthcare spending in emerging economies
Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al
BR+ NAD therapy is an IV protocol developed in 2001 at the Springfield Wellness Center in Springfield, Louisiana
One notable differentiator: Effecty explicitly states its 503A compounding pharmacies provide semaglutide that contains the same active ingredient found in Ozempic and Wegovy, and specifically avoids semaglutide salts, which are different compounds that have drawn FDA scrutiny at other platforms
For patients seeking dual-compound therapy, the GLP-Squared injection option launches at $289/mo (or $249/mo on the 3-month plan), combining semaglutide and tirzepatide into a single injection protocol
